-+ 0.00%
-+ 0.00%
-+ 0.00%

JOHNSON & JOHNSON REPORTS 75% TUMOR RESPONSE RATE IN ADVANCED PROSTATE CANCER WITH JNJ-6143, A FIRST-IN-CLASS RIPTAC™ MOLECULE

Reuters·10/25/2026 07:30:00

Please log in to view news